Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4).
Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition.
This has resulted in a strong need for better therapeutics such as incretin based drugs.
Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells.
The global Incretin-Based Drugs market is valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2026, growing at a CAGR of xx% during 2021-2026. The objectives of this study are to define, segment, and project the size of the Incretin-Based Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Incretin-Based Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Incretin-Based Drugs in these regions.
This research report categorizes the global Incretin-Based Drugs market by top players/brands, region, type and end user. This report also studies the global Incretin-Based Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
This report covers the present status and the future prospects of the global Incretin-Based Drugs market for 2015-2026.
The report offers detailed coverage of Incretin-Based Drugs industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Incretin-Based Drugs by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Glucagon-like peptide-1 receptor (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
Market Segment as follows:
Market by Order Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Market size by End User
Oral Drugs
Injectable Drugs
market while maintaining their competitive edge over their competitors. The report offers detailed and crucial information to understand the overall market scenario.
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Incretin-Based Drugs market for the forecast period 2021 - 2026?
• What are the driving forces in the Incretin-Based Drugs market for the forecast period 2021 - 2026?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Incretin-Based Drugs industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?
Note – In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.